UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
September 19, 2006
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Nevada
|
|
000-49616
|
|
88-0488686 |
| |
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
|
|
| 11588 Sorrento Valley Road, Suite 17, San Diego, California |
|
92121 |
| |
|
|
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 794-8889
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 3.02 Unregistered Sales of Equity Securities
On September 19, 2006, Halozyme Therapeutics, Inc. (the “Company”) issued 2,204,188 shares
(the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), in
connection with the exercise of callable Common Stock purchase warrants (“Warrants”). The Shares
were sold at a per share purchase price of $1.75 per share and the Company received gross proceeds
of approximately $3.9 million.
No shareholder approval was required for the sale of the Shares. The holders of the Warrants
are institutional and accredited investors as defined in the Securities Act of 1933, as amended
(the “Securities Act”), and the Shares were sold pursuant to exemptions from registration under
Regulation D of the Securities Act.
The Company has previously filed a registration statement with the Securities and Exchange
Commission covering the resale of the Shares.